Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations

Journal of the American Academy of Dermatology

Volumn 50, Issue 4, 2004, Pages 495-528

  Wu, Jashin J ^a,b   Huang, David B ^a,c   Pang, Katie R ^a,b   Tyring, Stephen K ^a,d,e  

^a Center for Clinical Studies ^*

^b Center for Clinical Studies

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIHISTAMINIC AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; DNA; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA A ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LYME DISEASE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PEDIARIX; POLIOMYELITIS VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANTHRAX; ARTHRALGIA; BRAIN DISEASE; CHICKENPOX; DIPHTHERIA; DRUG EFFICACY; DRUG INDICATION; ECZEMA; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; ERYTHEMA MULTIFORME; FATIGUE; FEVER; GRAM NEGATIVE INFECTION; HEADACHE; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HISTORY OF MEDICINE; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFECTION; INFLUENZA; INJECTION PAIN; LICHEN PLANUS; LYME DISEASE; LYMPHADENOPATHY; MALAISE; MEASLES; MENINGOCOCCOSIS; MUMPS; PAROTITIS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; RASH; REVIEW; RUBELLA; SMALLPOX; STREPTOCOCCUS INFECTION; TETANUS; THROMBOCYTOPENIC PURPURA; VACCINATION; VACCINE PRODUCTION; VASCULITIS; YELLOW FEVER;

EID: 1642358002     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.12.003     Document Type: Review

References (358)

1. CDC. Ten great public health achievements: United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:241-3.
2. CDC. Achievements in public health, 1900-1999: impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-8.
3. Bonanni P. Demographic impact of vaccination: a review. Vaccine 1999;17(Suppl 3):S120-5.
4. Wright PF, Kim-Farley RJ, de Quadros CA, Robertson SE. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991;325:1774-9.
5. Brundtland GH. State of the world's vaccines and immunizations. JAMA 2002;288:2532.
6. CDC. Measles update: measles activity through week 52 (ending Dec 28, 2002). National Immunization Program 2003;3:1-4.
7. Heyward W, MacQueen K, Goldenthal K. HIV vaccine development and evaluation: realistic expectations. AIDS Res Hum Retroviruses 1998;14(Suppl 3)S205-10.
8. Henderson DA, Moss B. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999. p. 74-97.
9. Is smallpox history? Lancet 1999;353:1539.
10. LeDuc JW, Becher J. Current status of smallpox vaccine. Emerg Infect Dis 1999;5:593-4.
11. Roizman B, Joklik W, Fields B, Moss B. The destruction of smallpox virus stocks in national repositories: a grave mistake and a bad precedent. Infect Agents Dis 1994;3:215-7.
12. Joklik W. The remaining smallpox virus stocks are too valuable to be destroyed. Scientist 1996;10:11.
13. Breman JG, Henderson DA. Poxvirus dilemmas: monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998;339:556-9.
14. Smallpox eradication: destruction of variola virus stocks. Paper presented at: World Health Assembly, May 24, 1999.
15. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva (Switzerland): World Health Organization; 1988.
16. Lane JM, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med 2003;138: 488-93.
17. CDC. Smallpox response plan and guidelines (version 3.0). Atlanta (GA): U.S. Department of Health and Human Services; 2002.
18. Bicknell W, James K. The new cell culture smallpox vaccine should be offered to the general population. Rev Med Virol 2003;13:5-15.
19. Arita I. Duration of immunity after smallpox vaccination: a study on vaccination policy against smallpox bioterrorism in Japan. Jpn J Infect Dis 2002;55:112-6.
20. Breman J, Henderson D. Diagnosis and management of smallpox. N Engl J Med 2002;346:1300-8.
21. CDC. Update: cardiac-related events during the civilian smallpox vaccination program-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:492-6.
22. Cono J, Casey CG, Bell DM, CDC. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003;52:1-28.
23. Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997;133:987-90.
24. Wharton M, Cochi S, Williams W. Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990;4:47-73.
25. CDC. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-57.
26. Preblud SR. Some issues relating to rubella vaccine. JAMA 1985;254:253-6.
27. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995;332:1262-6.
28. Gellin BG, Katz SL. Putting a stop to a serial killer: measles. J Infect Dis 1994;170(Suppl 1):S1-2.
29. Hope-Simpson RE. Infectiousness of communicable diseases in the household (measles, chicken pox, and mumps). Lancet 1952;2:549-54.
30. CDC. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR Morb Mortal Wkly Rep 1997;46:1-20.
31. CDC. Measles: United States, 1999. MMWR Morb Mortal Wkly Rep 2000;49:557-60.
32. CDC. Measles: United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:120-3.
33. CDC. Measles: United States, 2002. MMWR Morb Mortal Wkly Rep 2003;50:i-xxiv, 1-136.
34. Murray C, Lopez A. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-76.
35. Krause PJ, Cherry JD, Carney JM, Nalditch MJ, O'Connor K. Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am J Dis Child 1980;134: 567-71.
36. Watson JC, Pearson JA, Markowitz LE, Baughman AL, Erdman DD, Bellini WJ, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996;97:613-8.
37. Davis RM, Whitman ED, Orenstein WA, Preblud SR, Markowitz LE, Hinman AR. A persistent outbreak of measles despite appropriate control measures. Am J Epidemiol 1987;126:438-49.
38. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis 1983;5:477-81.
39. Mathias RG, Meekison WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989;79:475-8.
40. Reyes MA, de Borrero MF, Roa J, Bergonzoli G, Saravia NG. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 1987;6:848-51.
41. Pelota H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1986;1:939-42.
42. CDC. Measles: United States, 1988. MMWR Morb Mortal Wkly Rep 1989;38:601-5.
43. Modlin JF, Jabbour JT, Witte JJ, Halsey NA. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977;59:505-12.
44. CDC. Subacute sclerosing panencephalitis surveillance: United States. MMWR Morb Mortal Wkly Rep 1982;31:585-8.
45. Dyken PR. Subacute sclerosing panencephalitis, current status. Neurol Clin 1985;3:179-96.
46. Hilleman MR, Buynak EB, Weibel RE, Stokes J. Live, attenuated mumps vaccine. N Engl J Med 1968;278:227-32.
47. Weibel RE, Stokes J Jr, Buynak EB, Whitman JEJ, Hilleman MR. Live attenuated mumps: virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med 1967;276:245-51.
48. Sugg WC, Finger JA, Levine RH, Pagano JS. Field evaluation of live virus mumps vaccine. J Pediatr 1968;72:461-6.
49. Chaiken BP, Williams NM, Preblud SR, Parkin W, Altman R. The effect of a school entry law on mumps activity in a school district. JAMA 1987;257:2455-8.
50. Kim-Farley R, Bart S, Stetler H, Orenstein WA, Bart K, Sullivan KM, et al. Clinical mumps vaccine efficacy. Am J Epidemiol 1985;121:593-7.
51. Sullivan KM, Halpin TJ, Marks JS, Kim-Farley R. Effectiveness of mumps vaccine in a school outbreak. Am J Dis Child 1985;139: 909-12.
52. Wharton M, Cochi SL, Hutcheson RH, Bitowish JM, Schaffner W. A large outbreak of mumps in the post vaccine era. J Infect Dis 1988;158:1253-60.
53. Hersh BS, Fine PE, Kent WK, Cochi SL, Kahn LH, Zell ER, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-93.
54. CDC. Mumps surveillance: United States, 1988-1993. MMWR Morb Mortal Wkly Rep 1995;44(S-3):1-14.
55. Weibel RE, Buynak EB, McLean AA, Hilleman MR. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. Pediatrics 1978;61:5-11.
56. Chang TW, DesRosiers S, Weinstein L. Clinical and serologic studies of an outbreak of rubella in a vaccinated population. N Engl J Med 1970;283:246-8.
57. Bakshi SS, Cooper LZ. Rubella and mumps vaccines. Pediatr Clin North Am 1990;37:651-68.
58. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA 27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA 1973;225:585-90.
59. Gershon AA, Frey HM, Borkowsky W, Steinberg S. Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27/3 strains. Am J Med Sci 1980;279:95-7.
60. Hilleman M, Weibel R, Buynak E, Stokes JJ, Whitman JJ. Live attenuated mumps-virus vaccine: 4. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252-8.
61. Chu SY, Bernier RH, Stewart JA, Herrmann KL, Greenspan JR, Henderson AK, et al. Rubella antibody persistence after immunization: sixteen-year follow-up in the Hawaiian islands. JAMA 1988;259:3133-6.
62. O'Shea S, Best JM, Banatvala JE, Marshall WC, Dudgeon JA. Rubella vaccination: persistence of antibodies for up to 16 years. Br Med J (Clin Res Ed) 1982;285:253-5.
63. Kimberlin DW. Rubella immunization. Pediatr Ann 1997;26:366-70.
64. Freestone DS, Prydie J, Smith SG, Laurence G. Vaccination of adults with Wistar RA 27/3 rubella vaccine. J Hyg (Lond) 1971; 69:471-7.
65. Polk BF, Modlin JF, White JA, DeGirolami PC. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982;115:19-25.
66. Preblud S, Serdula M, Frank JJ, Brandling-Bennet A, Hinman A. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev 1980;2:171-94.
67. Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995;171(Suppl 1):S70-2.
68. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(Suppl 1):S44-9.
69. Horng YC, Chang MH, Lee CY, Safary A, André FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993;12:359-62.
70. Westblom TU, Gudipati S, DeRousse C, Midkiff BR, Belshe RB. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994; 169:996-1001.
71. Block SL, Hedrick JA, Tyler RD, Smith RA, Calandra G, Patterson C, et al. Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. Pediatr Infect Dis J 1993;12:976-80.
72. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
73. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
74. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-30.
75. Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996;49:235-41.
76. Damme PV, Thoelen S, Cramm M, Groote KD, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44:446-51.
77. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A vaccine: long term antibody persistence. Vaccine 1997;15:612-5.
78. Walin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993;18(Suppl 2):S51-5.
79. Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunization. Pediatrics 2001;108:1123-8.
80. Douglas RG. The heritage of hepatitis B vaccine. JAMA 1996; 276:1796-8.
81. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multicenter efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
82. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled trial in a high-risk population in the United States. N Engl J Med 1980;303:833-41.
83. Katkov WN, Dienstag JL. Hepatitis vaccines. Gastroenterol Clin North Am 1995;24:147-59.
84. Denis F, Mounier M, Hessel L, Michel JP, Gualde N, Dubois F, et al. Hepatitis B vaccination in the elderly. J Infect Dis 1984;149: 1019.
85. Heyward WL, Bender TR, McMahon BJ, Hall DB, Francis DP, Lanier AP, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 1985;121:914-23.
86. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-4.
87. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
88. Zimmerman RK, Ruben FL, Ahwesh ER. Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin. J Fam Pract 1997;45:295-315.
89. Thoelen S, Damme PV, Mathei C, Leroux-Roels G, Desombere I, Safary A, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708-14.
90. Heineman TC, Clements-Mann NL, Poland GA, Jacobson RM, Izu AE, Sakamoto D, et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999;17:2769-78.
91. Jilg W. Novel hepatitis B vaccines. Vaccine 1998;16(suppl): S65-8.
92. Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, et al. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat 1996;3:37-42.
93. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein: a preliminary study on immunogenicity. Vaccine 1992;10:439-42.
94. Bertino JS, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, Pre-S1, and Pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997;175:678-81.
95. Jilg W, Schmidt M, Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988;6:201-7.
96. Stevens CE, Taylor FE, Tong MJ, et al. Hepatitis B vaccine: an overview. In: Vyas GN, Dienstag JL, Hoofnagle JH, editors. Viral hepatitis and liver disease. Orlando: Grune & Stratton; 1984. p. 275-91.
97. Hadler S, Francis D, Maynard J, Thompson S, Judson F, Echenberg D, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315: 209-14.
98. Stevens C, Toy P, Taylor P, Lee T, Yip H. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992;90:170-3.
99. CDC. Notice to readers: availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999;48:780-2.
100. Andre F, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J 1987;63(Suppl 2):169-78.
101. CDC. Update: vaccine side effects, adverse reactions, contraindications and precautions-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-35.
102. Andre FE. Overview of 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990;8(suppl):74-8.
103. Neau D, Bonnet F, Michaud M, Perel Y, Longy-Boursier M, Ragnaud JM, et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis 1998;30:115-8.
104. Ronchi F, Cecchi P, Falcioni F, Marsciani A, Minak G, Muratori G, et al. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch Dis Child 1998;78:273-4.
105. Poullin P, Gabriel B. Thrombocytopenic purpura after recombinant hepatitis B vaccine. Lancet 1994;334:1293.
106. Hello CL, Cohen P, Bousser MG, Letellier P, Guillevin L. Suspected hepatitis B vaccination related vasculitis. J Rheumatol 1999;26:191-4.
107. Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax 1993;48:580-1.
108. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998;25:1687-93.
109. Rebora A, Rongioletti F, Drago F, Parodi A. Lichen planus as a side effect of HBV vaccination. Dermatology 1999;198:1-2.
110. Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination. Australas J Dermatol 1997;38:1S2-4.
111. Chen DS. Control of hepatitis B in Asia: mass immunization program in Taiwan. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991. p. 716-9.
112. Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, et al. Safety immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr Infect Dis J 2001;20:973-80.
113. Partridge S, Yeh SH. Clinical evaluation of a DTaP-HepB-IPV combined vaccine. Am J Manag Care 2003;9:S13-22.
114. Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivates Polio-virus Vaccine Combined] prescribing information. Rixensart [Belgium]: SmithKline Beecham Biologicals; 2002.
115. CDC. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and polio-virus vaccine combined (Pediarix) for use in infants. MMWR Morb Mortal Wkly Rep 2003;52:203-4.
116. Zepp F, Schuind A, Meyer C, Sanger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 2002;109:e58.
117. CDC. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and polio-virus vaccine combined (Pediarix) for use in infants. Erratum in: MMWR Morb Mortal Wkly Rep 2003;52:379.
118. CDC. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48:1-5.
119. Arvin AM. Varicella vaccine: the first six years. N Engl J Med 2001;344:1007-9.
120. Vazquez M, LaRussa PS, Gershon AA, Steinberg SO, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955-60.
121. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284:1271-9.
122. White C. Varicella-zoster virus vaccine. Clin Infect Dis 1997;24: 753-63.
123. Takahashi M. Clinical overview of varicella vaccine: development and early studies. Pediatrics 1986;78:736-41.
124. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94:524-6.
125. Weibel R, Neff B, Kuter B, Guess H, Rothenberger C, Fitzgerald A, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984;310:1409-15.
126. Kuter B, Weibel R, Guess H, Matthews H, Morton D, Neff B, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:643-7.
127. Watson BM, Keller PM, Ellis RW, Starr SE. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 1990;162:794-9.
128. White C, Kuter B, Hildebrand C, Isganitis K, Matthews H, Miller W, et al. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-10.
129. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995;20:316-9.
130. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis 1994;169:197-9.
131. Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985;75:667-71.
132. White C, Kuter B, Ngai A, Hildebrand C, Isganitis K, Patterson C, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11:19-23.
133. Watson B, Piercy S, Plotkin S, Starr S. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
134. Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, et al. Post-exposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8.
135. Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults: Oka/Merck Varicella Vaccine Study Group. Vaccine 1995;13:967-72.
136. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. The Varicella Vaccine Collaborative Study Group. N Engl J Med 1991;325: 1545-50.
137. Heller L, Berglund G, Ahström L, Hellstrand K, Wahren B. Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden. Postgrad Med J 1985;61(Suppl 4):79-83.
138. Gershon A, Steinberg S, Gelb L, Galasso G, Borkowsky W, La-Russa P, et al. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984;252:355-62.
139. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990;116: 184-9.
140. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, K KB, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002;347:26-34.
141. Miller A. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-7.
142. Burke BL, Steele RW, Beard OW. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142:291-3.
143. Hayward A, Levin M, Wolf W, Angelova G. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis 1991;163: 873-5.
144. Levin M, Murray M, Zerbe G, White C, Hayward A. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994;170:522-6.
145. Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178(Suppl 1):S109-12.
146. Levin JM. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2001;39:151-60.
147. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J 1995;14:874-9.
148. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-7.
149. Guess HA, Broughton DD, Melton LJ, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985;76:512-7.
150. Hammerschlag MR, Gershon A, Steinberg S, Clarke L, Gelb L. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989;160:535-7.
151. Gelb LD, Dohner DE, Gershon AA, Steinberg SP, Waner JL, Takahashi M, et al. Molecular epidemiology of live, attenuated varicella virus vaccine in children and in normal adults. J Infect Dis 1987;155:633-40.
152. White CJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am 1996;10:595-608.
153. Leppla S, Robbins J, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. J Clin Invest 2002;110: 141-4.
154. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 1985;49:291-7.
155. Uchida I, Hashimoto K, Terakado N. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids. J Gen Microbiol 1986;132:557-9.
156. Leppla SH. The bifactorial Bacillus anthracis lethal and oedema toxins. In: Alouf JE, Freer JH, editors. Comprehensive sourcebook of bacterial protein toxins. London: Academic Press, 1999. p. 243-63.
157. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 1989;171:722-30.
158. Puziss M. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl Microbiol 1963;11: 330-4.
159. Hambleton P, Carman JA, Melling J. Anthrax: the disease in relation to vaccines. Vaccine 1984;2:125-32.
160. Brachman PS. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:632-45.
161. FDA. Biological products: bacterial vaccines and toxoids; implementation of efficacy review. Proposed rule. Federal Register 50:1002-117.
162. Ministry of Labor (United Kingdom). Report of the Committee of Inquiry on Anthrax. London: Her Majesty's Stationery Office, 1959. p. 83.
163. Wright GG, Green TW, Kanode RG. Studies on immunity in anthrax. Immunizing activity of alum-precipitated protective antigen. J Immunol 1954;73:387-91.
164. Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001;19:3241-7.
165. CDC. Biosafetyin microbiological and biomedical laboratories. 4th ed. Washington, DC: US Department of Health and Human Services; 2000. p. 88-9.
166. Is it safe? Does it work? In: Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL, editors. The anthrax vaccine. Washington, DC: National Academy Press; 2002. p. 265.
167. Puziss M, Wright GG. Studies on immunity in anthrax. Gel-adsorbed protective antigen for immunization of man. J Bacteriol 1963;85:230-6.
168. Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2000;19:213-6.
169. Turnbull PC, Broster MG, Carman J, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986;52:356-63.
170. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998;16:1141-8.
171. Welkos S, Little S, Friedlander A, Fritz D, Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001;147:1677-85,
172. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002;70:661-4.
173. Cohen S, Mendelson I, Aitboum Z, Kobiler D, Elhanany E, Bino T, et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun 2000;68:4549-58.
174. Welkos SL, Vietri NJ, Gibbs PH. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog 1993;14:381-8.
175. Barnard JP, Friedlander AM. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produced protective antigen. Infect Immun 1999;67:562-7.
176. Hassett DE, Whitton JL. DNA immunization. Trends Microbiol 1996;4:307-12.
177. Williamson ED, Beedham RJ, Bennett AM, Miller J, Baillie LW. Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol 1999;87:315-7.
178. Gu ML, Leppla SH, Klinman DM. Protection against anthrax by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 1999;17:340-4.
179. Development and testing of vaccines against anthrax. Request for proposal. Bethesda (MD): National Institute of Allergy and Infectious Diseases; 2002.
180. Advisory Committee on Immunization Practices (CDC). Recommendations for the use of Lyme disease vaccine. MMWR Morb Mortal Wkly Rep 1999;48:1-25.
181. Montgomery RR, Malawista SE, Feen KJ, Bockenstedt LK. Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. J Exp Med 1996;183:261-9.
182. Fikrig E, Feng W, Aversa J, Schoen RT, Flavell RA. Differential expression of Borrelia burgdorferi genes during erythema migrans and Lyme arthritis. J Infect Dis 1998;178:1198-201.
183. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci USA 1995;92:2909-13.
184. da Silva AM, Telford SR, Brunet L, Barthold S, Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996;183:271-5.
185. da Silva AM, Zeidner N, Zhang Y, Dolan M, Piesman J, Fikrig E. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect Immun 1999;67:30-5.
186. Probert WS, Crawford M, Cadiz RB, LeFebvre RB. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 1997;175:400-5.
187. Fikrig E, Barthold S, Kantor F, Flavell R. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 1992;60:773-7.
188. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990;250:553-6.
189. Gern L, Hu CM, Voet P, Hauser P, Lobet Y. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelli. Vaccine 1997;15:1551-7.
190. Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, Hauser P, et al. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine 1995;13:435-41.
191. Telford SR, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, et al. Efficacy of human Lyme disease vaccine formulations in a mouse model. J Infect Dis 1995;171:1368-70.
192. Fikrig E, Telford SR, Barthold SW, Kantor FS, Spielman A, Flavell RA. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 1992;89:5418-21.
193. Chang YF, Appel MJ, Jacobson RH, Shin SJ, Harpending P, Straubinger R, et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 1995;63:3543-49.
194. Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, et al. The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine 1997;15:1872-87.
195. Van Hoecke CV, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, et al. Evaluation of the safety, reactogenicity and immunologenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine 1996;14:1620-6.
196. Hoecke CV, Lebacq E, Beran J, Parenti D. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis 1994;28:1260-4.
197. Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998;339:209-15.
198. Schoen RT, Meurice F, Brunet C, Cretella S, Krause DS, Craft JE, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995;172:1324-9.
199. Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998;339:216-22.
200. Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001;161:554-61.
201. Lastavica CC, Wilson ML, Berardi VP, Spielman A, Deblinger RD. Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts. N Engl J Med 1989;320:133-7.
202. Rahn DW. Lyme vaccine: issues and controversies. Infect Dis Clin North Am 2001;15:171-87.
203. Peltola H, Käyhty H, Sivonen A, Mäkelä PH. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977;60:730-7.
204. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
205. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, et al. Efficacy of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987;317:717-22.
206. Eskola J, Peltola H, Käyhty H, Takala AK, Mäkelä PH. Finnish efficacy trials with Haemophilus influenzae type b vaccines. J Infect Dis 1992;165(Suppl 1):S137-8.
207. Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med 1990;323:1393-401.
208. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001;33(Suppl 4):S278-87.
209. CDC. Haemophilus influenzae type b vaccine. MMWR Morb Mortal Wkly Rep 1988;36:832.
210. CDC. Food and Drug Administration approval of use of a Haemophilus b conjugate vaccine for infants. MMWR Morb Mortal Wkly Rep 1990;39:925-6.
211. CDC. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40:1-7.
212. Black SB, Shinefield HR, Fireman B, Hiatt R. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J Infect Dis 1992;165(Suppl 1):S139-43.
213. Black S, Shinefield H, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 1991;10:97-104.
214. Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72.
215. Daum RS, Granoff DM. Lessons from the evaluation of immunogenicity. In: Ellis RW, Granoff DM, editors. Development and clinical uses of Haemophilus b conjugate vaccine. New York: Marcel Dekker; 1994. p. 291-312.
216. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;120:184-9.
217. CDC. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993;42:296-8.
218. Holmes SJ, Fritzell B, Guito KP, Esbenshade JF, Blatter MM, Reisinger KS, et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants. Am J Dis Child 1993;147:832-6.
219. Fritzell B, Plotkin S. Efficacy and safety of a Hoemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.
220. Paradiso PR, Hogerman DA, Madore DV, Keyserling H, King J, Reisinger KS, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:827-32.
221. Huang LM, Chang PF, Lee PI, Chiu HH, Tsai SY, Lee CY. Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTiter) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (Tetramune) in two-month-old infants. J Microbiol Immunol Infect 1998;31:180-6.
222. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
223. Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999. p. 183-221.
224. CDC. Progress toward elimination of Haemophilus influenzae type b disease among infants and children: United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998;47:993-8.
225. CDC. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children: United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002;51:234-7.
226. Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997;349:1197-202.
227. Dagan R, Fraser D, Greif Z, Keller N, Kaufstein M, Shazberg G, et al. A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Pediatr Infect Dis J 1998;17(Suppl 9):S198-203.
228. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides. J Exp Med 1969;129:1367-84.
229. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-20.
230. Liu TY, Gotschlich EC, Jonssen EK, Wysocki JR. Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide. J Biol Chem 1971;246:2849-58.
231. Makela PH, Peltola H, Kayhty H, Jousimies H, Pettay O, Ruoslahti E, et al. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136(suppl):S43-50.
232. Wahdan MH, Rizk F, el-Akkad AM, el-Ghoroury AA, Hablas R, Girgis NI, et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ 1973;48:667-73.
233. Wahdan M, Sallam S, Hassan M, Gawad AA, Rakha A, Sippel J, et al. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 1977;55:645-51.
234. Sanborn WR, Bencic Z, Cvjetanovic B, Gotschlich EC, Pollock TM, Sippel JE. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria. Prog Immunobiol Stand 1972;5:497-505.
235. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:1536-47.
236. Gold R, Lepow M, Goldschneider I, Draper T, Gotschlich E. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age. J Infect Dis 1978;138:731-5.
237. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:114-8.
238. Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000;19:144-50.
239. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80.
240. Granoff D, Gupta R, Belshe R, Anderson E. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4.
241. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998;280:1685-9.
242. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-508.
243. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6.
244. Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-6.
245. Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999;354:615-6.
246. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000;342:219-20.
247. Anderson EL, Bowers T, Mink CM, Kennedy DJ, Belshe RB, Harakeh H, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62:3391-5.
248. Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, et al. Safety and immunogenicity of a serogroup A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 1996;275:1499-503.
249. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360-3.
250. Rosenstein N, Levine O, Taylor JP. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998;279:435-9.
251. Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students). Committee on Infectious Diseases. Pediatrics 2000;106:1500-4.
252. CDC. Prevention and control of meningococcal disease and meningococcal diseases and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49:13-20.
253. Pediatrics AAo. Meningococcal infections. In: Pickering L, editor. Red book. Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2000.
254. The Jordan report: accelerated development of vaccines. Bethesda (MD): National Institute of Allergy and Infectious Diseases, 1998.
255. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-8.
256. McCarthy M. HIV vaccine fails in phase 3 trial. Lancet 2003;361:755-6.
257. Sandstöm E, Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999;353:1735-42.
258. Birx DL, Davis C, Ruiz N, et al. Results of a phase II double-blind multicenter, placebo controlled HIV therapeutic vaccine trial [abstract]. International Conference on AIDS. Vancouver, July 1996. Abstract 175.
259. Tsoukas CM, Raboud J, Bernard NF, et al. Immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immune deficiency. AIDS Res Hum Retroviruses 1998;14:483-90.
260. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naïve adults. J Infect Dis 1993;167:533-7.
261. Frey SE. HIV vaccines. Infect Dis Clin North Am 1999;13:95-112.
262. Oxford JS, Addawe M, Lambkin R. AIDS vaccine development: let a thousand flowers bloom. J Clin Pathol 1998;51:725-30.
263. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
264. Belshe RB, Stevens C, Gorse G, et al. Phase II evaluation of a live recombinant canarypox (AVLAC) vector HIV-1 vaccine with or without gp120 subunit HIV-1 vaccine [abstract]. International Society for Sexually Transmitted Diseases Research; July 11-14, 1999; Denver, CO. Abstract 227.
265. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, et al. Clad B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-401.
266. Evans T, Corey L, Clements-Mann ML, et al. CD8+CTL induced in AIDS Vaccine Evaluation Group phase I trials using canary-pox vectors (ALVAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. Paper presented at: World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
267. Doepel LK. NIAID opens first AIDS vaccine trial in Africa. NIAID News. National Institute of Allergy and Infectious Diseases, February 8, 1999.
268. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49.
269. Stephenson J. In HIV vaccine efforts, new strategies and patience are needed in equal measure. JAMA 2002;288:2671-2.
270. Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med 1997;3:526-32.
271. Frank SB. Formulized herpes virus therapy and neutralizing substance in herpes simplex. J Invest Dermatol 1938;1:267-82.
272. Straus S, Wald A, Kost R, McKenzie R, Langenberg A, Hohman P, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176:1129-134,
273. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999;282:331-40,
274. Leroux-Roels G, Moreau E, Desombere I, et al. Safety, humoral and cellular immune responses of three different doses of glycoprotein D(gD2t) in herpes simplex vaccine with aluminum and MPL. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; New Orleans.
275. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
276. Boursnell ME, Entwisle C, Blakely D, Roberts C, Duncan IA, Chisholm SE, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175:16-25.
277. McLean CS, Challanin DN, Duncan I, Boursnell ME, Jennings R, Inglis SC. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 1996;14:987-92.
278. McClements WL, Armstrong ME, Keys RD, Liu MA, Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93:11414-20.
279. Rouse BT, Nair S, Rouse RJ, Yu Z, Kuklin N, Karem K, et al. DNA vaccines and immunity to herpes simplex virus. Curr Top Microbiol Immunol 1998;226:69-78.
280. Meignier B, Longnecker R, Roizman R. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;58:602-14.
281. Cadoz M, Micoud M, Seigneurin JM. Phase I trial of R7020: a live-attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Anaheim [CA].
282. Reichman R, Balsley J, Carlin D, et al. Evaluation of the safety and immunogenicity of a recombinant HPV-11 L1 virus like particle vaccine in healthy adult volunteers. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC].
283. Zhang LF, Zhou J, Shao C, et al. A phase 1 trial of HPV 6 B virus like particles as immunotherapy for genital warts. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC].
284. Silva DD, Nieland J, Greenstone H, Schiller J, Kast W. Chimeric papillomavirus virus-like particles induce antigen-specific therapeutic immunity against tumours expressing the HPV-16 E7 protein. Paper presented at: International Papillomavirus Conference; January 9-15, 1999; Charleston [SC].
285. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
286. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
287. Lacey CJ, Monteiro EF, Thompson HS, et al. A phase IIa study of a therapeutic vaccine for genital warts. Paper presented at: Medical Society for the Study of Venereal Disease; July 1997; Oxford, England.
288. Duggan-Keen MF, Brown MD, Stacey SN, Stern PL. Papillomavirus vaccines. Front Biosci 1998;3:1192-208.
289. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997;65:3328-36.
290. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997;71:8467-74.
291. Krul M, Tijhaar E, Kleijne J, Loon AV, Nievers M, Schipper H. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996;43:44-8.
292. Ossevoort MA, Feltkemp MC, VanVeen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995;18:86-94.
293. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-43.
294. Kong YC, Levine HB. Experimentally induced immunity in the mycoses. Bacteriol Rev 1967;31:35-53.
295. Neely MN, Ghannoum MA. The exciting new future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000;19:897-914.
296. Casadevall A, Cassone A, Bistoni F, Cutler JE, Magliani W, Murphy JW, et al. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol 1998;36(Suppl 1):95-105.
297. Deepe GS. Prospects for the development of fungal vaccines. Clin Microbiol Rev 1997;10:585-96.
298. Bistoni F, Vecchiarellf A, Cenci E, Puccetti P, Marconi P, Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 1986;51:668-74.
299. Cassone A, Boccanera M, Adriani D, Santoni G, Bernardis FD. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619-24.
300. Fidel PL, Sobel JD. Protective immunity in experimental Candida vaginitis. Res Immunol 1998;149:361-73.
301. Bernardis FD, Boccanera M, Adriani DA, Spreghini E, Santoni G, Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997;65:3399-409.
302. Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998;66:5771-76.
303. Mencacci A, Torosantucci A, Spaccapelo R, Romani L, Bistoni F, Cassone A. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun 1994;62:5353-60.
304. Mizutani S, Endo M, Ino-ve T, Kurosawa M, Uno Y, Salto H, et al. CD4-T-cell-mediated resistance to systemic candidiasis induced by a membrane fraction of Candida albicans. Antimicrob Ag Chemother 2000;44:2653-8.
305. Cardenas-Freytag L, Cheng E, Mayeux P, Domer JE, Clements JD. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun 1999;67:826-33.
306. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995;63:2714-9.
307. Han Y, Ulrich MA, Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 1999;179:1477-84.
308. Devi SJ. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 1996;14:841-4.
309. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
310. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000;13:122-43.
311. Hanel H, Kirsch R, Schmidts HL, Kottmann H. New systematically active antimycotics from the beta-blocker category. Mycoses 1995;38:251-64.
312. Tesh RB. Control of zoonotic visceral leishmaniasis: is it time to change strategies? Am J Trop Med Hyg 1995;52:287-92.
313. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996;55:125-30.
314. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001;14:229-43.
315. Schallig HD, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Trop Med Int Health 2002;7:641-51.
316. Ulmer JB, Sadoff JC, Liu MA. DNA vaccines. Curr Opin Immunol 1996;8:531-6.
317. Wahren B. Gene vaccines. Immunotechnology 1996;2:77-83.
318. Hassan UA, Abai AM, Harper DR, Wren BW, Morrow WJ. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999;229:1-22.
319. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a T helper cell type 1 response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998;9:1899-907.
320. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-47.
321. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001;69:4719-25,
322. Gurunathan S, Wu C, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000;12:442-7.
323. Klinman DM, Takeshita F, Kamstrup S, Takeshita S, Ishii K, Ichino M, et al. DNA vaccines: capacity to induce auto-immunity and tolerance. Dev Biol 2000;104:45-51.
324. Mor G, Eliza M. Plasmid DNA vaccines. Immunology, tolerance and autoimmunity. Mol Biotechnol 2001;19:245-50.
325. Ivens AC, Blackwell JM. The Leishmania genome comes of age. Parasitol Today 1999;15:225-31.
326. Dickler HB, Gelfand EW. Current perspectives on the use of intravenous immunoglobulin. Adv Intern Med 1996;41:641-80.
327. CDC. Renal insufficiency and failure associated with immune globulin intravenous therapy: United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21.
328. Bean B. Antiviral therapy: current concepts and practices. Clin Microbiol Rev 1992;5:146-82.
329. Bernstein LJ, Krieger BZ, Novick B, Sicklick MJ, Rubinstein A. Bacterial infections in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis J 1985;4:472-5.
330. Calvelli TA, Rubinstein A. Intravenous gamma-globulin in infant acquired immunodeficiency syndrome. Pediatr Infect Dis J 1986;5(Suppl 3):S207-10.
331. Gupta A, Novick BE, Rubinstein A. Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment. Am J Dis Child 1986;140:143-6.
332. Oleski JM, Connor EM, Bohila R, et al. Treatment of immunodeficiency virus antibody positive children with intravenous immunoglobulin. Vox Sang 1987;52:162-75.
333. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. Controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994;331:1181-7.
334. Hadler SC, Erben JJ, Matthews D, Starko K, Francis DP, Maynard JE. Effect of immunoglobulin on hepatitis A in day-care centers. JAMA 1983;249:48-53.
335. Krugman S, Ward R, Giles JP, Jacobs AM. Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection. JAMA 1960;174:883-90.
336. Woodson RD, Clinton JJ. Hepatitis prophylaxis abroad. JAMA 1976;209:1053-9.
337. Lauchart W, Muller R, Pichlmayr R. Immunoprophylaxis of hepatitis B viral reinfection in recipients of human liver allografts. Transplant Proc 1987;19:2387-9.
338. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-5.
339. Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 1997;4(Suppl 1):111-6.
340. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-36.
341. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314:560-3.
342. IVIG transmission of hepatitis C. FDA Med Bull 1994;24:3-4.
343. Maldonado YA. Current controversies in vaccination: vaccine safety. JAMA 2002;288:3155-8.
344. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
345. National Center for Health Statistics. National vital statistics system for numbers of death. Washington, DC: US Bureau of Census; 2001.
346. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch Dis Child 2002;87:22-5.
347. Wolfe RM, Sharp LK, Lipsky MS. Content and design attributes of antivaccination web sites. JAMA 2002;287:3245-8.
348. Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
349. Murphy W, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72.
350. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001;285:1183-5.
351. Kaye JA, Melero-Montes MdM, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001;322:460-3.
352. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002;347:1477-82.
353. Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-32.
354. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001;344:319-26.
355. Karvonen M, Cepaltis Z, Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study. BMJ 1999;318:1169-72.
356. Graves PM, Barriga KJ, Norris JM, Hoffman MR, Yu L, Eisenbarth GS, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999;22:1694-7.
357. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998;4:607-9.
358. Arakawa T, Langridge WH. Plants are not just passive creatures! Nat Med 1998;4:550-1.